Constructive on ABBV defensive compounder but disciplined on entry; scale via three tranches with stop at $250 and Q3 2026 earnings as binary catalyst gate
Overweight is the correct synthesis: the structural fundamental thesis (Skyrizi/Rinvoq reacceleration with Q2'26 revenue +10.2% YoY at all-time high $16.99B, PEG 0.54 on forward EPS of $16.26, 1.4-1.5x FCF dividend coverage, 2.62% Aristocrat yield, beta 0.28 defensive profile) warrants portfolio exposure — but disciplined entry via staged tranches avoids the 9/04 alpha-destruction pattern of adding at 52-week highs. Upgrade to Buy requires: Skyrizi/Rinvoq combined quarterly growth sustained ≥25% YoY with raised guidance AND restored disclosure AND FCF recovery above $4B quarterly. Downgrade to Hold/Underweight requires: Skyrizi quarterly print below 15% YoY, OR negative pre-announcement, OR tavapadon Phase 3 failure, OR 10Y Treasury sustainably above 5.25%, OR breakdown below $250 on volume.
| Position | Action |
|---|---|
| Close below $248 on volume | Exit remainder of position (100%) |
| Close below $250 | Exit 50% of position |
| 50 SMA zone pullback $255-260 | Add 35% of intended position |
| Confirmed close above $270.57 on volume >5M shares | Add final 30% of intended position |
| Entry zone $263-266 | Initiate 35% of intended position |
ABBV has transitioned from patent cliff risk to sustainable double-digit growth driven by Skyrizi and Rinvoq, with valuation metrics (PEG 0.54, forward P/E 16.37x) significantly underpricing the company's defensive growth characteristics and pipeline optionality.
| Indicator | Value | Signal |
|---|---|---|
| RSI (14) | 61.53 | bullish |
| MACD | 2.72 | bullish |
| MACD Signal | 2.42 | bullish |
| MACD Histogram | +0.31 | bullish |
| Bollinger Upper Band | 270.57 | neutral |
| Bollinger Middle Band | 260.62 | neutral |
| Bollinger Lower Band | 250.67 | neutral |
| ATR (14) | 5.16 | neutral |
| 10 EMA | 263.83 | bullish |
| 50 SMA | 257.28 | bullish |
| 200 SMA | 228.64 |
This report is AI-generated for informational and educational purposes only and is not investment advice or a recommendation to buy or sell any security. Full disclaimer.
When: Pullback to $255-260 (50 SMA confluence at $257.28)
Then: Buy 35% of intended position
↩ rebuts: “Near 52-week highs concern misses the significant upside runway”
EV: +9%
ABBV at $266 with 75x TTM P/E is priced for perfection with two drugs (Skyrizi/Rinvoq) underwriting the franchise; the next patent cliff is already scheduled for 2027-2031, making the risk/reward symmetric with downside tilt rather than asymmetric upside.
EV: -8.7% (~$243 probability-weighted target vs $266 current price; including 2.62% dividend, approximately -6% expected total return) · concedes: Management's conservative guidance framing may prove accurate if they under-promise and over-deliver; Humira patent cliff worst is largely behind the company; AbbVie may be a wonderful business (wonderful businesses can be terrible stocks at wrong price); Juvmo represents a legitimate FDA approval and first-in-class selective D1/D5 mechanism; Special charges ( Allergan litigation, IPR&D) can be argued as one-time vs structural; Forward P/E of 16.37x is reasonable on standalone basis; $240-250 entry levels would be attractive on macro-driven selloff; 2.62% dividend yield provides income support for existing holders
→ vs conservative: Waiting for pullback to 50 SMA at $257.28 misses the point—scaling plan already bakes in that dip opportunity with 50% reserved capital
→ vs conservative: Citing 'light catalyst path until Q3 earnings' ignores four major catalysts: Juvmo FDA approval September 25 (first-in-class Parkinson's treatment launching October), Iambic AI partnership, ADARx IPO stake ($1.74B RNA exposure), and EPKINLY Health Canada approval
→ vs conservative: Macro concerns about higher-for-longer rates ignore ABBV's 0.28 Beta—healthcare gets bid during equity volatility, and recession probability is only 8%
→ vs conservative: Valuation concerns miss that stock trades below consensus target despite 10% revenue growth and PEG of 0.54
→ vs neutral: Reading 10 EMA flattening as weakness when it represents normal consolidation before breakout, not exhaustion
→ vs neutral: Waiting for confirmation above $270.57 gives back half the move—trend-follower logic reduces risk-reward from 1.5:1 to 1:1
| bullish |
| Close | 266.28 | neutral |
| Open | 264.33 | neutral |
| High | 267.73 | neutral |
| Low | 263.38 | neutral |
| Volume | 4,393,401 | neutral |
Support: 250.67 · 255.96 · 257.28 · 260.62 · 261.12 | Resistance: 263 · 267 · 270.57 · 275 · 280
ABBV exhibits a mature bull trend across all timeframes with higher highs and higher lows intact since the April 2026 low of ~$196. Short-term momentum is positive but decelerating as evidenced by a flattening 10 EMA and a tight 6-session consolidation range of $263–$266 beneath the July–August highs near $267. The MACD histogram recently flipped positive (from -0.52 on 2026-09-15 to +0.31), confirming a fresh bullish impulse, while RSI has room to run toward 70 before reaching overbought territory. A breakout above the upper Bollinger Band at $270.57 would target $275–$280; a failure to clear $260.62 (Bollinger mid) would signal trend weakening with next support at the 50 SMA ($257.28).
Market Cap
$470.5B
P/E (TTM)
75.01
Forward P/E
16.37
PEG Ratio
0.54
P/B
-79.27
EPS (TTM)
$3.55
Forward EPS
$16.26
Dividend Yield
2.62%
52-Week High
$269.39
52-Week Low
$190.75
50-Day MA
$257.05
200-Day MA
$230.56
Beta
0.281
TTM Revenue
$64.39B
TTM Gross Profit
$46.87B
TTM EBITDA
$30.76B
TTM Net Income
$6.27B
Gross Margin
72.8%
Operating Margin
40.0%
Adjusted EBITDA Margin
~47.8%
ROA (TTM)
10.5%
Total Assets
$135.1B
Total Debt
$70.8B
Net Debt
$64.3B
Net Debt / EBITDA
~2.1x
Stockholders' Equity
-$5.9B
Current Ratio
0.81
TTM FCF
$16.87B
Annual Dividends
~$11.7B
Annual Buybacks
~$1.0B
CapEx (TTM)
~$1.2B
Q2'26 Revenue YoY Growth
+10.2%
Q2'26 EPS YoY Growth
+290%
2025 Revenue YoY Growth
+8.6%
2025 Normalized EBITDA YoY Growth
+28%
2022 Revenue
$58.05B
2023 Revenue
$54.32B
2024 Revenue
$56.33B
2025 Revenue
$61.16B
2025 Net Income
$4.23B
2025 Normalized EPS
~$4.22
Annual Amortization (Intangibles)
~$7.4B
Goodwill + Intangibles
$84.66B
Interest Expense
~$2.9B
R&D (Annual Run-rate)
~$9.1B
FCF / Revenue
~26%
Strengths
Concerns
AbbVie is a high-quality, defensive mega-cap pharma (~$470.5B market cap) that has successfully navigated the post-Humira cliff, with Q2 2026 revenue growing +10.2% YoY to $16.99B as Skyrizi and Rinvoq drive reacceleration, and 2025 revenue recovering to $61.2B (+8.6% YoY). The company demonstrates elite cash generation with TTM FCF of $16.87B and adjusted EBITDA margins of ~47.8%, supporting its 2.62% dividend (11 consecutive years of growth) with a sustainable ~66% payout ratio, though leverage remains elevated at Net Debt/EBITDA of ~2.1x ($70.8B total debt) and GAAP earnings are heavily compressed by ~$7.4B annual intangible amortization plus ~$5B in special charges. The forward P/E of 16.4x and PEG of 0.54 suggest the market is underpricing the growth trajectory, with TTM EPS expected to rebound sharply from $3.55 toward the $16.26 forward estimate.
Macro: Higher-for-longer interest rates dominant with 97% implied probability of no Fed cuts in 2026 ($8.6M traded); 0% probability on 6+ cuts ($13M+). US recession 2026 at 8% probability ($2.2M, +2.0pp WoW); UK 10%, Japan 4%. Treasury yields climbing with Dow, S&P 500, and Nasdaq slipping. Kevin Warsh hawkish signals framed as negative for pharma dividends; Mark Zandi warns higher rates damaging economy. Healthcare index bid late Monday. Risk-off rotation into select pockets.